TRT and Heart Health: What the
Research Actually Shows

If you've ever searched "testosterone therapy heart risk," you've probably encountered a confusing mix of alarming headlines, reassuring studies, and contradictory expert opinions. The cardiovascular safety of testosterone replacement therapy has been one of the most debated topics in men's health for over a decade — and for good reason. Heart disease is the leading killer of men in the United States, and any therapy that could increase or decrease that risk deserves careful scrutiny.

At Revive Low T Clinic, we believe our patients deserve the full picture — not cherry-picked data points designed to either scare you away from treatment or sell you on it without nuance. This article walks through the actual research, including the landmark TRAVERSE trial, explains what we monitor and why, and gives you the context you need to make an informed decision with your physician.

A Brief History of the Controversy

The cardiovascular concerns around TRT trace back primarily to two studies published in 2010 and 2013. The first was the TOM trial (Testosterone in Older Men with Mobility Limitations), a small study of frail elderly men that was stopped early when the testosterone group showed a higher rate of cardiovascular events. The second was a retrospective VA study by Vigen et al., published in JAMA, which suggested that men prescribed testosterone after coronary angiography had higher rates of heart attack and stroke.

Both studies made major headlines. The FDA issued a safety warning in 2015, and prescriptions for testosterone dropped significantly. But here's what the headlines didn't mention: both studies had serious methodological problems. The TOM trial studied men who were already frail with significant comorbidities — a population very different from the typical TRT patient. The Vigen study had statistical errors so significant that over 160 medical professionals signed an open letter to JAMA requesting retraction. The authors later published corrections, and subsequent re-analyses of the same data found no increased cardiovascular risk.

Despite these issues, the narrative of "testosterone is dangerous for the heart" became entrenched in public consciousness and even influenced how some primary care physicians approached TRT. It took nearly a decade — and a purpose-built cardiovascular safety trial — to provide a definitive answer.

The TRAVERSE Trial: The Study That Changed Everything

The Testosterone Replacement Therapy for Assessment of Long-Term Vascular Events and Efficacy Response in Hypogonadal Men (TRAVERSE) trial was specifically designed by the FDA to resolve the cardiovascular safety question once and for all. Published in the New England Journal of Medicine in 2023, it remains the largest and most rigorous randomized controlled trial ever conducted on testosterone therapy and heart health.

Here's what made TRAVERSE different from previous studies. It enrolled 5,246 men aged 45 to 80 who had documented hypogonadism (low testosterone confirmed by blood tests) and who also had pre-existing cardiovascular disease or were at high cardiovascular risk. This wasn't a study of healthy young men — these were patients who would be most vulnerable to cardiovascular harm if testosterone truly posed a cardiac risk. The study was randomized, double-blinded, and placebo-controlled with a mean follow-up period of 33 months.

The primary outcome was MACE — major adverse cardiovascular events, which includes cardiovascular death, nonfatal heart attack, and nonfatal stroke. The result: testosterone therapy did not increase the incidence of MACE compared to placebo. The hazard ratio was 0.96, with a confidence interval that confirmed noninferiority. In plain language, men taking testosterone had no higher rate of heart attacks, strokes, or cardiovascular death than men taking a placebo — even in a population already at high cardiac risk.

Meta-Analyses: What the Broader Data Shows

Beyond TRAVERSE, multiple meta-analyses — studies that combine data from many individual trials — have examined the cardiovascular safety of testosterone therapy. A comprehensive 2018 meta-analysis published in Expert Opinion on Drug Safety reviewed 35 randomized controlled trials encompassing over 5,600 men and found no statistically significant increase in cardiovascular events among men receiving testosterone therapy compared to placebo.

A 2020 analysis in the Journal of the American Heart Association actually found that testosterone therapy was associated with improved cardiovascular risk factors, including reductions in fasting glucose, insulin resistance (HOMA-IR), total cholesterol, and triglycerides. Another large observational study published in the European Heart Journal followed over 83,000 veterans with low testosterone and found that men who received TRT and achieved normal testosterone levels had significantly lower rates of heart attack, stroke, and all-cause mortality compared to untreated men.

It's important to note that observational studies can't prove causation — they can only show associations. But the pattern across the evidence base is remarkably consistent: when testosterone therapy is properly prescribed, dosed, and monitored, it does not appear to increase cardiovascular risk and may offer protective benefits for some men.

How Testosterone Actually Affects the Cardiovascular System

To understand the relationship between testosterone and heart health, it helps to understand what testosterone does in the cardiovascular system. Testosterone receptors are found throughout the heart and blood vessels. At physiological (normal) levels, testosterone has several cardiovascular effects that are generally beneficial.

First, testosterone promotes vasodilation — the widening of blood vessels — which can lower blood pressure and improve blood flow. Multiple studies have demonstrated that testosterone therapy can produce modest reductions in blood pressure in hypogonadal men. Second, testosterone influences body composition in ways that are cardiovascular favorable: it reduces visceral fat (the metabolically dangerous fat around your organs) and increases lean muscle mass. Since visceral fat is a major driver of metabolic syndrome, insulin resistance, and cardiovascular disease, this body composition shift is significant.

Third, testosterone affects lipid profiles — though the direction depends on dosing. At physiological replacement doses, testosterone tends to lower total cholesterol and triglycerides while having variable effects on HDL ("good") cholesterol. Supraphysiological doses (the kind used in anabolic steroid abuse) tend to significantly suppress HDL, which is why the cardiovascular data from steroid abuse should never be confused with therapeutic TRT. Fourth, testosterone modulates inflammation and has been shown to reduce inflammatory markers like C-reactive protein and interleukin-6 in hypogonadal men receiving replacement therapy.

The Hematocrit Factor: A Real Consideration

While TRAVERSE confirmed that TRT does not increase cardiovascular events, there is one cardiovascular-adjacent risk that requires monitoring: hematocrit elevation. Testosterone stimulates erythropoiesis — the production of red blood cells. This is actually one of the beneficial effects for many men, as it increases oxygen-carrying capacity and can improve energy and exercise performance.

However, when hematocrit rises too high (generally above 52-54%), blood becomes thicker and more viscous, which theoretically increases the risk of blood clots. This is the most commonly cited cardiovascular concern with TRT, and it's one that we take seriously at Revive. The TRAVERSE trial did find a higher incidence of pulmonary embolism in the testosterone group (0.9% vs. 0.5%), though total venous thromboembolism rates were not statistically different. This underscores the importance of regular hematocrit monitoring.

Here's how we manage this at Revive. Every patient gets a complete blood count (CBC) as part of their initial 51-analyte lab panel before starting therapy. We recheck hematocrit at every follow-up lab draw — typically at 6 weeks after starting, then every 3 to 6 months. If hematocrit begins to rise above 50%, we have several management strategies available: adjusting the testosterone dose, modifying injection frequency, or in some cases recommending therapeutic phlebotomy (blood donation). The vast majority of patients maintain safe hematocrit levels with appropriate dosing and monitoring.

Cardiovascular Risk Factors We Monitor

At Revive, cardiovascular health monitoring is built into every treatment plan. Beyond hematocrit, here's what we track and why:

• Blood pressure — Measured at every office visit. While TRT generally has a neutral to beneficial effect on blood pressure, we watch for changes in patients with pre-existing hypertension.
• Lipid panel — Total cholesterol, LDL, HDL, and triglycerides. We track trends over time to ensure your lipid profile isn't moving in an unfavorable direction.
• Fasting glucose and HbA1c — Insulin resistance and diabetes are major cardiovascular risk factors. TRT can improve insulin sensitivity, and we monitor to confirm this is happening.
• Estradiol — Elevated estrogen from testosterone aromatization can contribute to fluid retention and potentially affect cardiac function. We keep estradiol in optimal range.
• Liver function — AST and ALT, which can provide indirect information about overall metabolic health and medication tolerance.
• Body composition trends — We track changes in weight, waist circumference, and body fat percentage as indirect measures of metabolic and cardiovascular risk.

Who Should Be Extra Cautious

While the evidence is reassuring for the vast majority of men, certain patients warrant closer cardiovascular monitoring when starting TRT. Men who have had a recent heart attack or stroke (within the past 6 months), men with uncontrolled heart failure, and men with a history of blood clots should discuss TRT with both their hormone physician and their cardiologist before starting therapy.

At Revive, we don't automatically exclude these patients — but we do require a more thorough cardiovascular evaluation, closer monitoring intervals, and potentially more conservative dosing strategies. The TRAVERSE trial actually included high-risk cardiovascular patients and still showed no increased risk, which is reassuring. But individualized care means evaluating each patient's complete risk profile, not just applying a one-size-fits-all protocol.

Low Testosterone Itself Is a Cardiovascular Risk Factor

One of the most underappreciated aspects of this discussion is that untreated low testosterone is itself associated with increased cardiovascular risk. Multiple large epidemiological studies have demonstrated that men with low testosterone levels have higher rates of metabolic syndrome, type 2 diabetes, atherosclerosis, and cardiovascular mortality compared to men with normal testosterone levels.

A 2011 meta-analysis published in the Journal of Clinical Endocrinology and Metabolism, encompassing over 12,000 men across 12 prospective studies, found that low testosterone was associated with a 35% increased risk of cardiovascular death. This association persisted even after adjusting for age, obesity, and other traditional cardiovascular risk factors.

The mechanism likely involves the metabolic consequences of low testosterone: increased visceral fat, insulin resistance, unfavorable lipid profiles, increased inflammation, and reduced vascular function. By restoring testosterone to physiological levels, TRT may address these underlying metabolic drivers of cardiovascular disease — which is why some researchers believe appropriately dosed TRT could actually be cardioprotective in hypogonadal men.

The Bottom Line

The evidence is clear: when prescribed at physiological doses to men with documented low testosterone and monitored with regular blood work, testosterone replacement therapy does not increase the risk of heart attack, stroke, or cardiovascular death. The TRAVERSE trial — the largest, most rigorous study ever conducted on this question — confirmed this even in men who already had cardiovascular disease or were at high risk.

That said, TRT is not without cardiovascular considerations. Hematocrit monitoring is essential. Blood pressure, lipid panels, and other metabolic markers should be tracked regularly. And men with recent cardiovascular events should undergo additional evaluation before starting therapy.

This is precisely why comprehensive, in-person care matters. At Revive, every patient receives a 51-analyte lab panel, regular follow-up blood work, and ongoing physician oversight. We don't just prescribe testosterone — we monitor the full range of cardiovascular and metabolic markers that tell us whether your treatment is safe and effective. If you've been avoiding TRT because of cardiovascular concerns, the science suggests those concerns — while once understandable — are no longer supported by the evidence. The conversation with your physician should focus not on whether TRT is safe for your heart, but on whether it's right for your overall health picture.